Carregant...
Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival
Glioblastoma-multiforme (GBM), the most aggressive glial tumor, has a worldwide age-adjusted incidence ranging from 0.59-3.69/100000 persons. Despite current multimodal-treatment approach, median-survival time and progression-free survival (PFS) remains short. Glioblastomas display a variety of mole...
Guardat en:
| Publicat a: | World J Clin Cases |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5480073/ https://ncbi.nlm.nih.gov/pubmed/28685138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v5.i6.247 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|